×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Applying Principles of Global Regulatory Collaboration to Address Chronic Disease
Session Chair(s)
Brad Jordan, PhD
Associate Vice President, Regulatory Policy and Strategy
Eli Lilly and Company, United States
This session will focus on assessing the effectiveness of current regulatory collaboration efforts and identifying how those principles can be applied to chronic disease areas outside of oncology, such as metabolic disease and obesity.
Learning Objective : Describe the impact of global regulatory collaboration on patient outcomes; Understand risks associated with chronic disease and its impact on society as a whole; Identify innovative ways to address chronic disease through regulatory innovation and collaboration.
Speaker(s)
Project ORBIS and ACCESS Experience
Representative Invited
Health Canada, Canada
Applying Learnings from Project ORBIS
Representative Invited
FDA, United States
Considerations for Regulatory Collaboration in Chronic Disease
Representative Invited
FDA, United States
Industry Perspective
Kevin Bugin, PhD, MS, RAC
Amgen, United States
Head of Global Regulatory Policy and Intelligence
Have an account?